Merck & Co. Inc. (MRK) Stock Price Prediction
Price target with bull & bear cases · AI-assisted, editorially reviewed · Re-evaluated every trading day
Our AI model’s current price target for MRK is $155.00 — 5.5% above the latest price of $146.94.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for MRK is underpinned by its robust and expanding oncology pipeline beyond Keytruda, with ongoing clinical trials and potential new indications. [24, 32] Successful launches and label expansions of new drugs like Winrevair (sotatercept) are expected to drive significant revenue. [20] Strategic acquisitions, such as those of Acceleron Pharmaceuticals, Cidara Therapeutics, and Terns, are actively replenishing the company's product lineup. [20, 29, 32] Positive clinical trial data presentations, particularly at events like ESMO 2026, could re-rate shares. [24, 33] Continued strong demand for Keytruda in existing and new indications, alongside solid performance in its animal health segment, will also contribute to growth. [29, 32]
Bear Case
The primary bear case concern for MRK is the looming U.S. patent exclusivity loss for its blockbuster cancer drug Keytruda in 2028, which currently accounts for a substantial portion of the company's total revenue. [20] The stock's high valuation (P/E ratios) and a relatively high debt-to-equity ratio [9, 22, 26, 27] create elevated market expectations for sustained growth, which may be difficult to meet. Analysts have also downgraded EPS expectations, [19] and some profitability metrics like net margin, ROE, ROIC, and operating margin are declining. [23] Intense competition in the pharmaceutical market and potential challenges for products like the Gardasil vaccine in certain markets, such as China, also pose risks. [25, 33]
Model-assessed risk level: Medium
Key Catalysts to Watch
Upcoming clinical trial data readouts, especially in oncology at ESMO 2026 and for its TL1a program. [24, 33]
Successful commercialization and further label expansions of new drugs like Winrevair (sotatercept) for pulmonary arterial hypertension. [20]
Strategic acquisitions and pipeline advancements in areas beyond Keytruda. [20, 29, 32]
Q3 earnings report, expected in the coming weeks, which will provide insight into recent performance and guidance. [2]
Developments and manufacturing progress for the personalized cancer vaccine in collaboration with Moderna. [24, 33]
Technical Backdrop
RSI-14
50.7
50-Day MA
$144.78
200-Day MA
$117.76
From 52-Wk High
-7.1%
Full momentum breakdown: Is MRK overbought or oversold?
Model Notes
Merck & Co., Inc. (MRK) is a global healthcare company focused on prescription medicines, vaccines, and animal health products. The company demonstrates strong market performance, particularly within its oncology portfolio led by Keytruda, and is actively expanding its pipeline through R&D and strategic acquisitions. Despite facing the upcoming patent expiry for Keytruda, analysts generally hold a positive outlook, although concerns exist regarding its valuation and certain financial health metrics.
MRK exhibits strong development within a rising trend channel over the medium term, indicating increasing investor optimism and a potential for continued upward movement. [4] The stock is currently trading near the top of its 52-week range. [3, 8] Most moving averages (including 20, 50, 100, and 200-day exponential and simple moving averages) signal a 'Buy'. [5, 7] While the short-term trend is neutral, the long-term trend remains positive. [8] The Relative Strength Index (RSI) is in a neutral range, [5, 7, 8] and the Moving Averages Convergence Divergence (MACD) indicator suggests a 'Buy' signal. [5, 7]
Current Street Context
October 15, 2026The AI price target of $159.35 for Merck aligns with a "Buy" consensus rating from analysts as of October 14, 2026. The average analyst price target is $159.26, with a range from $105 to $186, suggesting a potential upside of 10.5% from current levels. Merck is scheduled to report its Q3 2026 earnings on October 29, 2026, with analysts projecting an EPS of $2.12. While fiscal 2026 EPS is expected to decline, a substantial rebound of 248.5% is anticipated in fiscal 2027. Key upcoming events include the presentation of pivotal Phase 3 trial results from its oncology pipeline at the ESMO Congress 2026, featuring data on intismeran autogene and sacituzumab tirumotecan. Merck's strategy to diversify its growth beyond Keytruda, focusing on cardiopulmonary, infectious disease, and animal health assets, is expected to support long-term earnings growth. These targets are estimates and not guarantees.
Frequently Asked Questions
What is the price target for MRK?
How is this forecast generated?
How accurate are stock price predictions?
Will MRK stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews MRK’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on MRK
Merck & Co. Inc. Overview
Price, chart, analysis & financials
MRK: Overbought or Oversold?
Updated daily
MRK: Why Is It Moving?
Updated daily
MRK: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers